
## Feras Abu Saadeh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10195399/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	HE4 and CA125 as preoperative risk stratifiers for lymph node metastasis in endometrioid carcinoma of the endometrium: A retrospective study in a cohort with histological proof of lymph node status. Gynecologic Oncology, 2021, 160, 514-519.	1.4	14
2	Update on extended prophylaxis for venous thromboembolism following surgery for gynaecological cancers. Thrombosis Update, 2021, 2, 100038.	0.9	3
3	Use of an artificial mammary implant in total pelvic exenteration. International Journal of Gynecological Cancer, 2021, 31, 1186-1187.	2.5	5
4	Procoagulant activity in high grade serous ovarian cancer patients following neoadjuvant chemotherapy-The role of the activated protein C pathway. Thrombosis Research, 2021, 200, 91-98.	1.7	4
5	The value of human epididymis 4, <scp>D</scp> â€dimer, and fibrinogen compared with CAÂ125 alone in triaging women presenting with pelvic masses: a retrospective cohort study. Acta Obstetricia Et Gynecologica Scandinavica, 2021, 100, 1239-1247.	2.8	2
6	Cachexia in treatment-naÃ <sup>-</sup> ve gynecological cancer patients: Prevalence, predictors, and clinical associations Journal of Clinical Oncology, 2021, 39, e17576-e17576.	1.6	0
7	A risk score for prediction of venous thromboembolism in gynecologic cancer: The Thrombogyn score. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 848-859.	2.3	13
8	Laparoscopic Boari flap formation in advanced ovarian carcinoma. International Journal of Gynecological Cancer, 2020, 30, 1081-1081.	2.5	0
9	Lung metastases from benign uterine leiomyoma: does 18-FDG-PET/CT have a role to play?. Irish Journal of Medical Science, 2019, 188, 619-624.	1.5	8
10	Sister Mary Joseph nodule: an unusual site for endometrioid cancer metastasis. BMJ Case Reports, 2019, 12, e229187.	0.5	3
11	Patients' experience and compliance with extended low molecular weight heparin prophylaxis post-surgery for gynecological cancer: a prospective observational study. International Journal of Gynecological Cancer, 2019, 29, 802-809.	2.5	12
12	Peri operative venous thromboembolism prophylaxis in gynaecological cancer patients. A survey of current practice. Thrombosis Research, 2016, 145, 126-128.	1.7	9
13	Procoagulant activity in gynaecological cancer patients; the effect of surgery and chemotherapy. Thrombosis Research, 2016, 139, 135-141.	1.7	23
14	Paravaginal aggressive angiomyxoma. BMJ Case Reports, 2015, 2015, bcr2014207287-bcr2014207287.	0.5	3
15	Suspected ovarian molar pregnancy after assisted reproductive technology conception: a diagnostic challenge. BMJ Case Reports, 2015, 2015, bcr2015209353-bcr2015209353.	0.5	3
16	Co-Operative Radical Pelvic Surgery. International Journal of Gynecological Cancer, 2015, 25, 931-936.	2.5	0
17	Could Sentinel Node Mapping of the Groin Cause Extranodal Metastasis in Vulva Cancer?. Gynecologic and Obstetric Investigation, 2015, 79, 280-284.	1.6	1
18	A novel serum microRNA panel to discriminate benign from malignant ovarian disease. Cancer Letters, 2015, 356, 628-636.	7.2	71

#	Article	IF	CITATIONS
19	An unusual relapse in acute myeloid leukaemia. BMJ Case Reports, 2015, 2015, bcr2014207395-bcr2014207395.	0.5	1
20	An unusual presentation of endometriosis. BMJ Case Reports, 2014, 2014, bcr2014204270-bcr2014204270.	0.5	4
21	Tumour expresion of tissue factor and tissue factor pathway inhibitor in ovarian cancer- relationship with venous thrombosis risk. Thrombosis Research, 2013, 132, 627-634.	1.7	51
22	Venous thromboembolism in ovarian cancer: incidence, risk factors and impact on survival. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2013, 170, 214-218.	1.1	94
23	Opportunistic and interventional salpingectomy in women at risk: a strategy for preventing pelvic serous cancer (PSC). European Journal of Obstetrics, Gynecology and Reproductive Biology, 2013, 170, 251-254.	1.1	35
24	Pre-Treatment of Platinum Resistant Ovarian Cancer Cells with an MMP-9/MMP-2 Inhibitor Prior to Cisplatin Enhances Cytotoxicity as Determined by High Content Screening. International Journal of Molecular Sciences, 2013, 14, 2085-2103.	4.1	23